 |
|
|
ARGX Description — argenx SE
argenx is a clinical-stage biotechnology company developing differentiated therapies for the treatment of severe autoimmune diseases and cancer. Co. is developing its main product candidate, efgartigimod, for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris and chronic demyelinating polyneuropathy, all of which are severe autoimmune diseases associated with high levels of circulating pathogenic immunoglobulin G antibodies for which there are few biologic treatments and a severe unmet medical need exists. Co. is also developing cusatuzumab in hematological cancer indications, acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.
| Company Name: |
argenx SE |
| Website: |
www.argenx.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding ARGX: |
12 |
| Total Market Value Held by ETFs: |
$63,941,164 |
|
| ETF |
ARGX Weight |
ARGX Amount |
| FBT |
3.25% |
$35,902,799 |
| SPDW |
0.09% |
$17,679,793 |
| QQQJ |
0.80% |
$5,272,766 |
| QEFA |
0.14% |
$1,336,317 |
| CWI |
0.08% |
$1,214,499 |
| BIB |
0.92% |
$751,885 |
| SPEU |
0.17% |
$482,855 |
| EFAX |
0.14% |
$391,216 |
| IBBQ |
1.26% |
$385,695 |
| FTQI |
0.11% |
$296,264 |
| List of all 12 ETFs holding ARGX
» |
|
|
|
|
|
Strong Buy (3.52 out of 4)
60th percentile
|
PARTNER NEWS:Tue, Apr 23, 11:16 AM, Zacks
GSK Gears Up for Q1 Earnings: Here's What to Expect
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
Fri, Mar 22, 8:28 AM, Zacks
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
|
|
Free ARGX Email Alerts:
